奈必洛尔联合缬沙坦治疗原发性高血压有效性和安全性分析

Efficacy and safety of nebivolol combined with valsartan in patients with essential hypertension

目的观察奈必洛尔联合缬沙坦治疗原发性高血压的有效性和安全性。方法选取98例原发性高血压患者随机分为观察组和对照组,对照组采用缬沙坦进行治疗,观察组采用奈必洛尔联合缬沙坦治疗,2个月后查看疗效和不良反应。结果 8周后观察组治疗总有效率为95.9%,对照组为79.6%,差异比较具有统计学意义(P<0.05);治疗4周和8周后,观察组收缩压、舒张压及静息心率均明显低于对照组,差异比较具有统计学意义(P<0.05);治疗4周及8周后观察组血压达标率均明显高于对照组,差异比较有统计学意义(P<0.05);对照组与缬沙坦有关的不良反应2例,发生率为4.1%。观察组与2种药品有关的不良发应3例,发生率6.1%,2组不良反应率比较差异无统计学意义(P>0.05)。结论奈必洛尔联合缬沙坦治疗原发性高血压疗效显著,安全性高,可在临床上进一步推广。

Objective To evaluate the efficacy and safety of nebivolol combined with valsartan in patients with essential hypertension. Methods Totally 98 patients with essential hypertension were randomly divided into a control group and a treatment group： patients in the control group received valsartan, and those in the treatment group got nebivolol combined with valsartan. The clinical efficacy and adverse reaction of the 2 groups were compared 2 months later. Results After 8 weeks, the total efficacy rate of the treatment group was 95.9% and that of the control group was 79.6%, with significant difference （P 〈 0.05）; The systolic blood pressure, diastolic blood pressure and resting heart rate of the treatment group were significantly lower than those of the control group, with significant difference （P 〈 0.05）; The blood pressure control rate of the treatment group was significantly higher than that of the control group （P 〈 0.05）; The adverse reaction rate of the treatment group was 6.1% while that for the control group was 4.1%, with no significant difference between the 2 groups （P 〉 0.05）. Conclusion Nebivolol combined with valsartan for essential hypertension is safe and effective, which can be applied in clinical practice.